Conference spotlight puts Harrow’s ophthalmic pipeline in focus Harrow (HROW) is set to present 15 scientific abstracts ...

With two highly differentiated branded prescription products, Harrow believes it can give eyecare professionals greater flexibility to individualize treatment based on their patients' needs and ...

Harrow (HROW) said Monday that it has closed its earlier stated acquisition of Tyrvaya from Viatris (VTRS), acquiring worldwide rights to the nasal spray, except for Japan. Harrow ...

Harrow has invested $30 million on a nasal spray for dry eye disease and could spend an additional $70 million on the deal.

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...

Harrow Inc (NASDAQ:HROW) and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement on Monday. Harrow acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ...

Harrow’s Q3 revenue grew 44% YoY to $49.3 million, supported by increased prescriptions for Vevye and Iheezo. High SG&A costs of $33.6 million in Q3 sustained Harrow’s net loss despite gross margin ...

Was the transaction executed via direct or indirect ownership, and what entities were involved? All shares were disposed of indirectly through Opaleye, L.P. and a separately managed account, with ...

Harrow Health stock was trading at USD 30.69 on Nasdaq at 1:56 p.m. ET on October 5, 2026, up 0.69 percent on the session.

Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug ...